Axitinib (AG 013736) is a potent multi-target tyrosine kinase inhibitor (TKI), which inhibits VEGFR1, VEGFR2, VEGFR3, PDGFR?, PDGFR? and c-Kit with IC50 values of 1.2 nM, 0.2 nM, 0.1 nM-0.3 nM, 1.6 nM, 5.0 nM, and 1.7 nM, respectively. [1] In human xenograft tumor models (nude mice), Axitinib (AG 013736) shows consistent antitumor efficacy across various tumor types, which is associated with reduction in vascular angiogenesis and tumor proliferation and increase in tumor apoptosis. [1]Axitinib (AG 013736) resulted in significantly longer progression-free survival compared with sorafenib and has been approved as a second-line therapy of advanced renal cell carcinoma. [2]

Technical information:

Shipping Condition: The product is shipped in a glass vial at ambient temperature.Storage condition: For longer shelf life, store solid powder or DMSO solution at -20^oC desiccated.

Reference:

Other Information:

Product Specification (pdf) MSDS (pdf) Certificate of Analysis is available upon request.

Cellagen利用广泛的研究以及我们在干细胞生物学，药物化学和产品开发方面的专业知识，Cellagen长期以来一直为专业OEM产品提供世界领先的公司，为一线干细胞研究奠定了基础。

现在，Cellagen扩展了其最佳产品系列，并直接向研究界提供。Cellagen与世界领先的科学家有着密切的联系，并且始终认识到高标准科学研究的未满足需求。